- Home
- LUCY vs MYNZ Comparison
LUCY vs MYNZ Comparison
Compare LUCY & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUCY
- MYNZ
- Stock Information
- Founded
- LUCY 2017
- MYNZ 2021
- Country
- LUCY United States
- MYNZ Germany
- Employees
- LUCY N/A
- MYNZ N/A
- Industry
- LUCY Ophthalmic Goods
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- LUCY Health Care
- MYNZ Health Care
- Exchange
- LUCY Nasdaq
- MYNZ Nasdaq
- Market Cap
- LUCY 8.7M
- MYNZ 7.9M
- IPO Year
- LUCY 2022
- MYNZ 2021
- Fundamental
- Price
- LUCY $1.97
- MYNZ $1.58
- Analyst Decision
- LUCY
- MYNZ Buy
- Analyst Count
- LUCY 0
- MYNZ 2
- Target Price
- LUCY N/A
- MYNZ $14.00
- AVG Volume (30 Days)
- LUCY 634.0K
- MYNZ 435.5K
- Earning Date
- LUCY 11-11-2025
- MYNZ 09-26-2025
- Dividend Yield
- LUCY N/A
- MYNZ N/A
- EPS Growth
- LUCY N/A
- MYNZ N/A
- EPS
- LUCY N/A
- MYNZ N/A
- Revenue
- LUCY $1,978,018.00
- MYNZ $659,935.00
- Revenue This Year
- LUCY $149.32
- MYNZ $26.06
- Revenue Next Year
- LUCY $400.00
- MYNZ $4.97
- P/E Ratio
- LUCY N/A
- MYNZ N/A
- Revenue Growth
- LUCY 29.30
- MYNZ N/A
- 52 Week Low
- LUCY $1.57
- MYNZ $1.28
- 52 Week High
- LUCY $10.40
- MYNZ $16.04
- Technical
- Relative Strength Index (RSI)
- LUCY 49.26
- MYNZ 47.54
- Support Level
- LUCY $1.94
- MYNZ $1.28
- Resistance Level
- LUCY $2.08
- MYNZ $1.73
- Average True Range (ATR)
- LUCY 0.12
- MYNZ 0.13
- MACD
- LUCY 0.00
- MYNZ 0.01
- Stochastic Oscillator
- LUCY 20.85
- MYNZ 65.95
About LUCY Innovative Eyewear Inc.
Innovative Eyewear Inc is engaged in developing and selling eyeglasses and sunglasses, which are designed to allow customers to remain connected to their digital lives, while also offering prescription eyewear and sun protection. Its products include Lucyd Lyte, Nautica, Eddie Bauer, Lucyd Armor line, and Reebok.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.